BDBM164867 US10604504, Example 20::US11623921, Example 20::US9688629, 20::US9802915, Example 20::US9920031, Example 20

SMILES CN(C(=O)C=C)c1cccc(c1C)-c1ccc(C(N)=O)c2[nH]c(C)c(C)c12

InChI Key InChIKey=FLXWWWSUNKRTEX-UHFFFAOYSA-N

Data  7 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 7 hits for monomerid = 164867   

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM164867(US9688629, 20 | US9802915, Example 20 | US9920031,...)
Affinity DataIC50: 0.590nMAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/22/2023
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM164867(US9688629, 20 | US9802915, Example 20 | US9920031,...)
Affinity DataIC50: 0.590nMAssay Description:Inhibition of recombinant human full-length His-tagged BTK cytoplasmic domain expressed in baculovirus expression system using fluorescence-labelled ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2020
Entry Details Article
PubMed
TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM164867(US9688629, 20 | US9802915, Example 20 | US9920031,...)
Affinity DataIC50: 0.590nMAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/20/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM164867(US9688629, 20 | US9802915, Example 20 | US9920031,...)
Affinity DataIC50: 0.590nMAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/4/2020
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM164867(US9688629, 20 | US9802915, Example 20 | US9920031,...)
Affinity DataIC50: 0.590nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2018
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM164867(US9688629, 20 | US9802915, Example 20 | US9920031,...)
Affinity DataIC50: 0.590nMAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/1/2019
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM164867(US9688629, 20 | US9802915, Example 20 | US9920031,...)
Affinity DataIC50: 61nMAssay Description:Inhibition of BTK in human Ramos cells assessed as reduction in intracellular calcium level incubated for 1 hr measured for 180 secs by FLIPR assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2020
Entry Details Article
PubMed